NCT05561543Completed
Effects of Peppermint Oil in Mild-moderate Hypertension.
Effects of Peppermint Oil in Cardiometabolic Outcomes in Participants With Mild-moderate Hypertension.
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
Cardiovascular and associated hypertensive diseases are the leading health burden and cause of mortality worldwide; therefore, the necessity for effective interventions is paramount. Dietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. Our previous randomized trial has shown that oral peppermint can improving systolic blood pressure and other cardiovascular/ blood lipids in healthy individuals. However, to date, no research has explored this using a placebo randomized intervention in patients with hypertension. Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in participants with mild-moderate hypertension.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 26 Sept 2022
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- University of Central Lancashire
- Diseases
- High blood pressure
- NCT number
- NCT05561543
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 1 Jan 2024 to the primary completion date, 1 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- known cardiovascular disease or clinically significant cardiovascular comorbidity, including coronary heart disease, symptomatic heart failure, clinically significant arrhythmia, or a history of stroke or transient ischaemic attack within the previous 6 months
- current enrolment in other clinical trials or use of other external therapies likely to influence outcomes
Other illness
- diagnosed diabetes mellitus
- known or suspected secondary hypertension, including renal, renovascular, or endocrine causes
- known clinically significant renal impairment or severe hepatic disease
- evidence or history of severe hypertension related target organ damage requiring specialist management
- allergy to peppermint
- condition(s) likely to compromise informed consent, protocol compliance, or outcome assessment, including severe psychiatric illness, cognitive impairment, or active substance or alcohol misuse.
Other
- pregnant or lactating women
- habitual consumption of peppermint products
- regular consumption of antioxidant supplements
- body mass index larger than 40.0 kg/m²
Who the study is looking for
- Aged from 18-65 years
- Systolic blood pressure 120 to 139 mmHg
- Not taking prescribed medicine for blood pressure management
- have the ability to complete written questionnaires independently
- Able to provide informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Central Lancashire Coordinator of this site? Confirm its status | Preston | United Kingdom | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.